Additional Runs. If any HEALTH AUTHORITIES request further analytical testing and/or production runs in addition to those described in EXHIBIT 11, BI Austria shall perform such testing and/or production runs as requested by InterMune. The cost of such additional testing and/or production runs will be borne by InterMune, subject to InterMune's prior written approval of such costs, unless the additional analytical testing and/or production runs are due to negligence on BI Austria's or BI Pharma KG's part. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 10 of 66
Appears in 2 contracts
Sources: Data Transfer, Clinical Trial and Market Supply Agreement (Intermune Pharmaceuticals Inc), Data Transfer, Clinical Trial and Market Supply Agreement (Intermune Pharmaceuticals Inc)